TransMedics (TMDX) Q2 Revenue Jumps 38%

TransMedics Group (TMDX 2.92%), a leader in organ transplant technology, released its second quarter 2025 earnings on July 30, 2025. The company topped Wall Street expectations, posting GAAP revenue of $157.4 million, ahead of the $147.7 million analyst estimate, and delivering GAAP earnings per share (EPS) of $0.92 —more than doubling consensus forecasts. GAAP revenue jumped 38.0% from the prior year, and management raised its full-year outlook, citing continued strong momentum in both its core Organ Care ...